Acorda Therapeutics Inc Price/Sales
What is the Price/Sales of Acorda Therapeutics Inc?
The Price/Sales of Acorda Therapeutics Inc is 0.11
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Acorda Therapeutics Inc
What does Acorda Therapeutics Inc do?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Companies with price/sales similar to Acorda Therapeutics Inc
- Sakuma Exports has Price/Sales of 0.11
- ATOS SE has Price/Sales of 0.11
- BRF S.A has Price/Sales of 0.11
- Guan Chao has Price/Sales of 0.11
- TCL Electronics has Price/Sales of 0.11
- TClarke Plc has Price/Sales of 0.11
- Acorda Therapeutics Inc has Price/Sales of 0.11
- Sintex Industries has Price/Sales of 0.11
- Kisan Mouldings has Price/Sales of 0.11
- EVRAZ Plc has Price/Sales of 0.11
- Transtech Optelecom Science has Price/Sales of 0.11
- ParcelPal Technology has Price/Sales of 0.11
- Hong Kong Johnson Hldg Co Ltd has Price/Sales of 0.11